SANOFI INDIA LIMITED
SANOFI.BOLoading price...
Overview
Previous Close3,366.90
Open3,365.45
Ask3,316.00
Bid3,311.00
Day's Range3,292.85 - 3,365.45
52 Week Range3,057.60 - 5,551.05
PE Ratio(TTM)24.69
Market Cap₹7,647Cr
Volume₹1,759
Avg. Volume₹8,810
Face Value₹NaN
Dividend Yield7.23%
Performance
ABSCAGR
| YTD | 1 Month | 3 Months | 1 Year | 2 Years | 5 Years | 10 Years | |
|---|---|---|---|---|---|---|---|
| No results to display | |||||||
Profit/Loss
Important Ratios
| PARTICULARS | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|
| Net Sales | ₹2,771 | ₹3,071 | ₹2,902 | ₹2,957 | ₹2,770 |
| Total Expenditure | ₹2,148 | ₹2,405 | ₹2,189 | ₹2,194 | ₹2,067 |
| Raw Materials | ₹1,206 | ₹1,345 | ₹1,196 | ₹1,264 | ₹1,201 |
| Employees | ₹407 | ₹450 | ₹461 | ₹434 | ₹406 |
| Selling, Administration Expenses | ₹224 | ₹227 | ₹148 | ₹156 | ₹160 |
| Power and Fuel Cost | ₹40 | ₹42 | ₹24 | ₹14 | ₹14 |
| Operating Profits | ₹623 | ₹665 | ₹713 | ₹762 | ₹703 |
| OPM% | 22.481% | 21.667% | 24.574% | 25.783% | 25.375% |
| Other Income | ₹90 | ₹94 | ₹90 | ₹75 | ₹73 |
| Depreciation | ₹103 | ₹100 | ₹82 | ₹67 | ₹42 |
| Interest | ₹1 | ₹0 | ₹2 | ₹2 | ₹2 |
| Profit Before Tax | ₹610 | ₹600 | ₹677 | ₹1,258 | ₹864 |
| Tax | ₹229 | ₹186 | ₹200 | ₹313 | ₹244 |
| Profit After Tax | ₹381 | ₹414 | ₹478 | ₹944 | ₹621 |
| Adjusted EPS | ₹165 | ₹180 | ₹208 | ₹411 | ₹270 |
| Net Profit Margin | 13.74% | 13.49% | 16.46% | 31.94% | 22.4% |
Company Profile
Sector: Healthcare
Industry: Drug Manufacturers - General
HQ Location: Mumbai, India
Country Lead, MD & GM of Pharma: Mr. Deepak Arora
Employees: 1,097
About Company:
Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company offers pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, anti-infectives, and central nervous system under the Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targocio, Combiflam, DePura, Allegra, Baralgan, BUSCOGAST, Dulcoflex, Enterogermina, Novalgin, and Avil brands through independent distributors. It also exports its products. The company was formerly known as Aventis Pharma Limited and changed its name to Sanofi India Limited in May 2012. The company was incorporated in 1956 and is headquartered in Mumbai, India. Sanofi India Limited operates as a subsidiary of Hoechst GmbH.